» Articles » PMID: 22101116

Evaluation of Multiple Risk-associated Single Nucleotide Polymorphisms Versus Prostate-specific Antigen at Baseline to Predict Prostate Cancer in Unscreened Men

Overview
Journal Eur Urol
Specialty Urology
Date 2011 Nov 22
PMID 22101116
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Although case-control studies have identified numerous single nucleotide polymorphisms (SNPs) associated with prostate cancer, the clinical role of these SNPs remains unclear.

Objective: Evaluate previously identified SNPs for association with prostate cancer and accuracy in predicting prostate cancer in a large prospective population-based cohort of unscreened men.

Design, Setting, And Participants: This study used a nested case-control design based on the Malmö Diet and Cancer cohort with 943 men diagnosed with prostate cancer and 2829 matched controls. Blood samples were collected between 1991 and 1996, and follow-up lasted through 2005.

Measurements: We genotyped 50 SNPs, analyzed prostate-specific antigen (PSA) in blood from baseline, and tested for association with prostate cancer using the Cochran-Mantel-Haenszel test. We further developed a predictive model using SNPs nominally significant in univariate analysis and determined its accuracy to predict prostate cancer.

Results And Limitations: Eighteen SNPs at 10 independent loci were associated with prostate cancer. Four independent SNPs at four independent loci remained significant after multiple test correction (p<0.001). Seven SNPs at five independent loci were associated with advanced prostate cancer defined as clinical stage≥T3 or evidence of metastasis at diagnosis. Four independent SNPs were associated with advanced or aggressive cancer defined as stage≥T3, metastasis, Gleason score≥8, or World Health Organization grade 3 at diagnosis. Prostate cancer risk prediction with SNPs alone was less accurate than with PSA at baseline (area under the curve of 0.57 vs 0.79), with no benefit from combining SNPs with PSA. This study is limited by our reliance on clinical diagnosis of prostate cancer; there are likely undiagnosed cases among our control group.

Conclusions: Only a few previously reported SNPs were associated with prostate cancer risk in the large prospective Diet and Cancer cohort in Malmö, Sweden. SNPs were less useful in predicting prostate cancer risk than PSA at baseline.

Citing Articles

A PSA SNP associates with cellular function and clinical outcome in men with prostate cancer.

Srinivasan S, Kryza T, Bock N, Tse B, Sokolowski K, Janaththani P Nat Commun. 2024; 15(1):9587.

PMID: 39505858 PMC: 11541583. DOI: 10.1038/s41467-024-52472-6.


Genetically adjusted PSA levels for prostate cancer screening.

Kachuri L, Hoffmann T, Jiang Y, Berndt S, Shelley J, Schaffer K Nat Med. 2023; 29(6):1412-1423.

PMID: 37264206 PMC: 10287565. DOI: 10.1038/s41591-023-02277-9.


Prostate cancer autoantibodies - applications in diagnosis, prognosis, monitoring disease progression and immunotherapy.

Jayakrishnan R, Schafer C, Tan S Am J Clin Exp Urol. 2023; 11(2):79-102.

PMID: 37168942 PMC: 10165224.


Genetic polymorphisms at 19q13.33 are associated with [-2]proPSA (p2PSA) levels and provide additional predictive value to prostate health index for prostate cancer.

Huang D, Ruan X, Wu Y, Lin X, Huang J, Ye D Prostate. 2021; 81(13):971-982.

PMID: 34254325 PMC: 8456816. DOI: 10.1002/pros.24192.


Single nucleotide polymorphisms (SNPs) in prostate cancer: its implications in diagnostics and therapeutics.

Allemailem K, Almatroudi A, Alrumaihi F, Almansour N, Aldakheel F, Rather R Am J Transl Res. 2021; 13(4):3868-3889.

PMID: 34017579 PMC: 8129253.


References
1.
Park J, Wacholder S, Gail M, Peters U, Jacobs K, Chanock S . Estimation of effect size distribution from genome-wide association studies and implications for future discoveries. Nat Genet. 2010; 42(7):570-5. PMC: 4615599. DOI: 10.1038/ng.610. View

2.
Hooker S, Hernandez W, Chen H, Robbins C, Torres J, Ahaghotu C . Replication of prostate cancer risk loci on 8q24, 11q13, 17q12, 19q33, and Xp11 in African Americans. Prostate. 2009; 70(3):270-5. DOI: 10.1002/pros.21061. View

3.
Stadler Z, Thom P, Robson M, Weitzel J, Kauff N, Hurley K . Genome-wide association studies of cancer. J Clin Oncol. 2010; 28(27):4255-67. PMC: 2953976. DOI: 10.1200/JCO.2009.25.7816. View

4.
Waters K, Le Marchand L, Kolonel L, Monroe K, Stram D, Henderson B . Generalizability of associations from prostate cancer genome-wide association studies in multiple populations. Cancer Epidemiol Biomarkers Prev. 2009; 18(4):1285-9. PMC: 2917607. DOI: 10.1158/1055-9965.EPI-08-1142. View

5.
FitzGerald L, Kwon E, Koopmeiners J, Salinas C, Stanford J, Ostrander E . Analysis of recently identified prostate cancer susceptibility loci in a population-based study: associations with family history and clinical features. Clin Cancer Res. 2009; 15(9):3231-7. PMC: 2707085. DOI: 10.1158/1078-0432.CCR-08-2190. View